share_log

With 67% Ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), Institutional Investors Have a Lot Riding on the Business

With 67% Ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), Institutional Investors Have a Lot Riding on the Business

擁有梯瓦製藥公司(紐交所:TEVA)67%股權的機構投資者對該業務有很多利害關係。
Simply Wall St ·  10/21 19:53

Key Insights

主要見解

  • Institutions' substantial holdings in Teva Pharmaceutical Industries implies that they have significant influence over the company's share price
  • The top 25 shareholders own 46% of the company
  • Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
  • 機構在梯瓦製藥的大量持股意味着他們對公司的股價具有重大影響
  • 前 25 名股東擁有該公司的 46%。
  • 所有權研究和分析師預測數據有助於更好地了解股票市場的機會。

If you want to know who really controls Teva Pharmaceutical Industries Limited (NYSE:TEVA), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 67% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果您想知道誰真正控制着梯瓦製藥工業有限公司(紐交所:TEVA),那麼您就必須查看其股東名冊的構成。我們可以看到,機構擁有該公司67%的所有權。換句話說,該集團最有可能(或最有可能)從他們對該公司的投資中獲益。

Last week's 4.1% gain means that institutional investors were on the positive end of the spectrum even as the company has shown strong longer-term trends. The gains from last week would have further boosted the one-year return to shareholders which currently stand at 119%.

上週的4.1%漲幅意味着機構投資者在這家公司表現出強勁的長期趨勢的同時也處於正面。 上週的收益進一步提升了股東的一年回報率,目前達到了119%。

Let's delve deeper into each type of owner of Teva Pharmaceutical Industries, beginning with the chart below.

讓我們深入研究梯瓦製藥業每種所有者,首先從下面的圖表開始。

big
NYSE:TEVA Ownership Breakdown October 21st 2024
紐交所:TEVA所有權分佈2024年10月21日

What Does The Institutional Ownership Tell Us About Teva Pharmaceutical Industries?

機構所有權對梯瓦製藥有何影響?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。

As you can see, institutional investors have a fair amount of stake in Teva Pharmaceutical Industries. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Teva Pharmaceutical Industries' earnings history below. Of course, the future is what really matters.

正如您所見,機構投資者在梯瓦製藥業擁有相當大比例的股權。 這可能表明該公司在投資社區中擁有一定的信譽度。 但是,最好謹慎依賴機構投資者所帶來的所謂認可。 他們也會犯錯誤。 如果多家機構同時改變對某隻股票的看法,您可能會看到股價迅速下跌。 因此值得查看下文中梯瓦製藥業的盈利歷史。 當然,未來才是真正重要的。

big
NYSE:TEVA Earnings and Revenue Growth October 21st 2024
紐交所:梯瓦製藥2024年10月21日的盈利和營業收入增長

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Teva Pharmaceutical Industries is not owned by hedge funds. Phoenix Investments & Finances Ltd is currently the largest shareholder, with 4.1% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 3.9% of common stock, and FMR LLC holds about 3.7% of the company stock.

機構投資者擁有公司超過50%的股份,因此他們很可能強烈影響董事會的決定。梯瓦製藥未由對沖基金擁有。菲尼克斯投資與金融有限公司目前是最大股東,持有公司已發行股份的4.1%。黑石集團,Inc.是第二大股東,擁有公司普通股的3.9%,而FMR LLC持有公司股份的約3.7%。

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

對我們的所有權數據進行更深入的研究表明,前25名股東的持股總額不到註冊表的一半,表明有一個小股東的大群體,其中沒有單個股東擁有多數股份。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

我們的數據表明,私人公司持有公司的4.0%的股份。單單從這個事實上很難得出任何結論,因此它值得研究誰擁有這些私人公司。有時內部人或其他相關方通過單獨的私營公司持有上市公司的股份。

Insider Ownership Of Teva Pharmaceutical Industries

梯瓦製藥的內部股權情況。

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間是不同的。我們的數據反映了個別內部人員,至少捕捉到了董事會成員。公司管理業務,但首席執行官即使是董事會成員也必須向董事會負責。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。

Our most recent data indicates that insiders own less than 1% of Teva Pharmaceutical Industries Limited. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$121m of stock. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

我們最近的數據顯示,內部持有人擁有梯瓦製藥工業有限公司不到1%的股份。 由於規模如此之大,我們不希望內部持有人擁有大量股份。 他們共持有價值12100萬美元的股票。 看到至少有一些內部持有是件好事,但也值得看看這些內部持有人是否一直在拋售。

General Public Ownership

一般大衆所有權

The general public-- including retail investors -- own 33% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

普通公衆--包括散戶股東--擁有公司33%的股權,因此他們無法輕易被忽略。儘管這種所有權尺寸可能不足以使政策決策朝他們的方向傾斜,但他們仍然可以對公司政策產生集體影響。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

我覺得查看公司的實際所有者非常有趣。但爲了真正獲得洞察力,我們需要考慮其他信息。

Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow.

很多人覺得深入了解一家公司過去的表現是有用的。您可以訪問此詳細的過去收益、營業收入和現金流量圖。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果您希望了解分析師在未來增長方面的預測,請務必不要錯過這份免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論